TXCELL

TxCell, a spin off of Inserm (France's National Institute for Health and Medical Research) located in the technology park of Sophia Antipolis, near Nice in southern France, is developing cell-based immuno-therapies for the treatment of severe chronic inflammatory diseases with high medical need using its unique and proprietary technology platform based on the properties of Type 1 regulatory T lymphocytes (Tr1 cells). The company has completed enrollment of a PhI/II study in refractory Crohn's disease patients and has reported first positive results. The company plans to initiate a PhIIb study in the same patient population and bring a second product candidate into a PhI/II study in refractory rheumatoid arthritis patients.

#SimilarOrganizations #People #Financial #Website #More

TXCELL

Social Links:

Industry:

Biotechnology Pharmaceutical Therapeutics

Founded:

2001-01-01

Address:

Valbonne, Provence-Alpes-Cote D'Azur, France

Country:

France

Website Url:

http://www.txcell.com

Total Employee:

51+

Status:

Active

Contact:

+33493641580

Email Addresses:

[email protected]

Total Funding:

66.1 M USD

Technology used in webpage:

Viewport Meta IPhone / Mobile Compatible SPF Google Font API Apache IPv6 Microsoft Azure DNS DigiCert SSL ReCAPTCHA V2 Encryption Everywhere

Similar Organizations

aztherapies-logo

AZTherapies

AZTherapies is a clinical stage biotech company developing breakthrough treatments for neuroinflammation-related diseases.

imcyse-logo

Imcyse

Developing disease specific immune therapies to treat severe, chronic auto-immune, inflammatory, allergic, infectious diseases and tumors.

Current Employees Featured

francois-meyer_image

Francois Meyer
Francois Meyer CEO @ TxCell
CEO

Founder

francois-meyer_image

Francois Meyer

Stock Details

Company's stock symbol is EPA:TXCL

Investors List

bpifrance_image

Official Site Inspections

http://www.txcell.com

Host Informations
Whois Informations

Loading ...